Fibromuscular dysplasia screening

Jump to navigation Jump to search

Fibromuscular dysplasia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Fibromuscular dysplasia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiorgram

X-ray

CT

MRI

Arteriography

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Management Guidelines

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

ASA/ACCF/AHA Guideline Recommendations

Management of Patients With Fibromuscular Dysplasia of the Extracranial Carotid Arteries

Case Studies

Case #1

Fibromuscular dysplasia screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Fibromuscular dysplasia screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Fibromuscular dysplasia screening

CDC on Fibromuscular dysplasia screening

Fibromuscular dysplasia screening in the news

Blogs on Fibromuscular dysplasia screening

Directions to Hospitals Treating Fibromuscular dysplasia

Risk calculators and risk factors for Fibromuscular dysplasia screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohsen Basiri M.D.

Overview

According to the American Heart Association (AHA)/American College of Cardiology guidelines, and European consensus on the diagnosis and management of fibromuscular dysplasia, there are some recommendations and indications for screening of FMD-related RAS ,cervicocephalic FMD, and in first-degree relatives of patients with FMD.

Screening

Renal artery fibromuscular dysplasia

  • According to the American Heart Association (AHA) / American College of Cardiology guidelines, and European consensus on the diagnosis and management of fibromuscular dysplasia among patients with HTN, screening for FMD-related RAS is recommended in the following indications:[1][2]
  1. Age <30 years, especially in women
  2. Grade 3 (_180/110 mmHg), accelerated or malignant HTN,
  3. Resistant HTN (blood pressure target not achieved despite triple therapy at optimal doses including a diuretic)
  4. Small kidney without history of uropathy
  5. Abdominal bruit without apparent atherosclerosis
  6. FMD in at least another vascular territory

Fibromuscular dysplasia of the cervicocephalic arteries

Screening for FMD of the cervico-cephalic arteries should be considered in case of retinal or cerebral ischemic events, intracranial aneurysms, subarachnoid hemorrhage, cervical or intracranial dissections, or pulsatile tinnitus. However, it should be kept in mind that none of these symptoms are specific of FMD. In particular, the existence of intracranial aneurysms is not sufficient to establish the diagnosis of FMD.

Screening for fibromuscular dysplasia in first-degree relatives

  • Hereditary FMD is possible in people with early-onset HTN, dissection, aneurysms, or cerebral hemorrhage.The presence of theses findings within the family members may provide an etiological clue, the patient must be informed about the possibility of hereditary FMD.
  • Individuals with hereditary FMD are more often demonstrate multifocal and bilateral renal artery lesions in contrast to sporadic ones.

References

  1. Alan T. Hirsch, Ziv J. Haskal, Norman R. Hertzer, Curtis W. Bakal, Mark A. Creager, Jonathan L. Halperin, Loren F. Hiratzka, William R. C. Murphy, Jeffrey W. Olin, Jules B. Puschett, Kenneth A. Rosenfield, David Sacks, James C. Stanley, Lloyd M. Jr Taylor, Christopher J. White, John White, Rodney A. White, Elliott M. Antman, Sidney C. Jr Smith, Cynthia D. Adams, Jeffrey L. Anderson, David P. Faxon, Valentin Fuster, Raymond J. Gibbons, Jonathan L. Halperin, Loren F. Hiratzka, Sharon A. Hunt, Alice K. Jacobs, Rick Nishimura, Joseph P. Ornato, Richard L. Page & Barbara Riegel (2006). "ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation". Journal of the American College of Cardiology. 47 (6): 1239–1312. doi:10.1016/j.jacc.2005.10.009. PMID 16545667. Unknown parameter |month= ignored (help)
  2. Alexandre Persu, Alessandra Giavarini, Emmanuel Touze, Andrzej Januszewicz, Marc Sapoval, Michel Azizi, Xavier Barral, Xavier Jeunemaitre, Alberto Morganti, Pierre-Francois Plouin & Peter de Leeuw (2014). "European consensus on the diagnosis and management of fibromuscular dysplasia". Journal of hypertension. 32 (7): 1367–1378. doi:10.1097/HJH.0000000000000213. PMID 24842696. Unknown parameter |month= ignored (help)
  3. J. Perdu, P. Boutouyrie, C. Bourgain, N. Stern, B. Laloux, E. Bozec, M. Azizi, C. Bonaiti-Pellie, P.-F. Plouin, S. Laurent, A.-P. Gimenez-Roqueplo & X. Jeunemaitre (2007). "Inheritance of arterial lesions in renal fibromuscular dysplasia". Journal of human hypertension. 21 (5): 393–400. doi:10.1038/sj.jhh.1002156. PMID 17330059. Unknown parameter |month= ignored (help)

Template:WH Template:WS